Answers are grounded in this paper and cite their sources.
There is a strong bidirectional tripartite link between the three main pancreatic diseases; diabetes mellitus (DM), pancreatitis and pancreatic cancer. The mechanisms driving these links are numerous and complex. However, a central nexus is metabolism and the control of low resting cytosolic Ca 2+ concentration ([Ca 2+ ] i ) in pancreatic cancer cells and pancreatic acinar cells. Specifically, in pancreatic cancer cells the upregulation of key glycolytic enzymes provides a privileged glycolytic ATP supply to the plasma membrane Ca 2+ ATPase (PMCA), or Ca 2+ pump, resulting in resistance to cell death, a key cancer hallmark response. Furthermore, insulin has a protective effect on pancreatic acinar cells during acute pancreatitis (AP), which occurs through a similar mechanism. Notably insulin drives glycolysis and thus ATP supply to the PMCA in pancreatic acinar cells, thereby preventing cytotoxic Ca 2+ overload and necrotic cell death, even in the face of impaired mitochondria. This mechanism offers a number of therapeutic intervention opportunities, albeit with diametrically opposite outcomes, for the treatment of pancreatic cancer and acute pancreatitis. In pancreatic cancer cells, strategies that block the PMCA or cut off the privileged ATP supply to the PMCA, using selective glycolytic inhibitors, have the potential to selectively kill pancreatic cancer cells, while sparing non-cancer cells that rely on mitochondria as a source of ATP. During AP, activation of similar downstream signalling pathways to insulin (using insulin-mimetics) would have the desired effect of boosting glycolytic ATP supply to the PMCA to prevent cytotoxic Ca 2+ overload and necrotic cell death, hallmarks of acute pancreatitis.
No takes yet. Share an insight, caveat, or question.
Bruce et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: